- Home
- HAIA
HAIA
Healthcare AI Acquisition Corp.
as 07-26-2024 4:00pm EST
Healthcare AI Acquisition Corp is a blank check company.
| Founded: | 2021 | Country: | Cayman Islands |
| Employees: | N/A | City: | DOVER |
| Market Cap: | 67.6M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 947.0 |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.19 | EPS Growth: | -88.13 |
| 52 Week Low/High: | $10.61 - $11.50 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Healthcare AI Acquisition Corp. News
HAIA Breaking Stock News: Dive into HAIA Ticker-Specific Updates for Smart Investing
ACCESSWIRE
7 days ago
Healthcare AI Acquisition Corp. Announces Receipt of Nasdaq Deficiency Letter
PR Newswire
6 months ago
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
Simply Wall St.
6 months ago
OMNIQ Corp. (NASDAQ:OMQS): Are Analysts Optimistic?
Business Wire
6 months ago
Marti introduces multi-modal subscription packages to increase rider usage and improve the operational efficiency of its two-wheeled electric vehicle business
ACCESSWIRE
6 months ago
Peraso Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
6 months ago
T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients
ACCESSWIRE
6 months ago
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
PR Newswire
6 months ago
NUVVE ANNOUNCES 1-FOR-40 REVERSE STOCK SPLIT
Compare HAIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HAIA Healthcare AI Acquisition Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.